Cresco Labs reported QQ3 2024 revenue of approximately $180 million, delivering improved profitability and robust cash flow despite ongoing pricing compression across core markets. Management highlighted a 53% adjusted gross margin and a 29% adjusted EBITDA margin for the quarter, with reported gross margin around 49.2% and EBITDA of $43.7 million. Quarterly operating income was $26.3 million, and net income of -$10.5 million, reflecting ongoing earnings volatility typical in a high-growth, highly regulated cannabis landscape. Importantly, the company generated $49.4 million of operating cash flow in the quarter and $103 million year-to-date, underscoring Cresco’s discipline around profitability and liquidity.
Cresco’s strategic focus rests on three pillars: (1) optimizing the footprint in core markets (notably Ohio, Florida and Pennsylvania), (2) sustaining leadership in branded wholesale products (Illinois, Pennsylvania and Massachusetts, with a growing Ohio position) and (3) building a high-productivity retail platform via Sunnyside in strategic states. The quarter featured a 1.6x uplift in Ohio sales from phased adult-use activities, continued leadership in branded share in Illinois, Pennsylvania and Massachusetts, and a notable 76% sales increase for two Pennsylvania dispensaries converted to the Sunnyside model. The company also retired $40 million of 2026 notes post-quarter, signaling a proactive balance sheet optimization ahead of refinancing.
Looking ahead, Cresco guided to a mid-single-digit year-over-year decrease in Q4 revenue versus Q3 and reiterated a target gross margin around 50%. Capex guidance for Q4 was raised to $20-25 million (bringing full-year Capex to $35-40 million), with expectations of higher cash generation continuing in 4Q and beyond. With a narrow net income line, the focus remains on sustainable operating cash flow and free cash flow to fund core reinvestment, potential M&A, and debt management. While near-term volatility persists due to market dynamics and regulatory considerations, Cresco’s balance sheet resilience, cash generation trajectory, and efficiency improvements position the stock to benefit from stabilized markets and potential long-term reforms in the cannabis landscape.